Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.38 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 4/20 | 0.37 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13255952 | 1.00 | KCNH2 (0.44) | KCNH2HRH3MAPTHPGDSMN1; SMN2 | |
| SCHEMBL11110219 | 0.94 | KCNH2 (0.46) | KCNH2HRH3HPGDSMN1; SMN2NPC1 | |
| SCHEMBL13657897 | 0.89 | MAOB (0.40) | SMN1; SMN2ALDH1A1SLC18A3MAOB | |
| SCHEMBL19662088 | 0.89 | KCNH2 (0.50) | KCNH2HRH3SMN1; SMN2PTGES2 | |
| SCHEMBL13241988 | 0.84 | KIF11 (0.37) | KCNH2HRH3MAPTSMN1; SMN2NPC1 | |
| SCHEMBL9772734 | 0.79 | KCNH2 (0.44) | KCNH2HRH3SMN1; SMN2PTGES2 | |
| SCHEMBL9772749 | 0.79 | SLC6A2 (0.44) | KCNH2HRH3HPGDSMN1; SMN2 | |
| SCHEMBL9772728 | 0.79 | KCNH2 (0.44) | KCNH2HRH3SMN1; SMN2PTGES2 | |
| SCHEMBL9772696 | 0.79 | KCNH2 (0.44) | KCNH2HRH3RAB9A | |
| SCHEMBL6308450 | 0.79 | SLC6A2 (0.44) | KCNH2HRH3HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0338010-B1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HYPERPROLIFERATE SKIN DISEASE | SCHERING CORPORATION (US) | 1992-02-05 | — | — | EP | claimed |
| EP-0228416-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZANAPHTHALENES | SCHERING CORPORATION (US) | 1990-03-21 | — | — | EP | claimed |
| CN-118222538-B | Halohydrin dehalogenase mutant and application thereof | 南京工业大学 | 2024-09-20 | — | — | CN | disclosed |
| CN-118620972-A | Application of halohydrin dehalogenase in catalytic synthesis of chiral tetrahydrofuran compound | 南京工业大学 | 2024-09-10 | — | — | CN | disclosed |
| CN-118222538-A | Halohydrin dehalogenase mutant and application thereof | 南京工业大学 | 2024-06-21 | — | — | CN | disclosed |
| US-20220387589-A1 | TRANS CAROTENOIDS, THEIR SYNTHESIS, FORMULATION AND USES | DIFFUSION PHARMACEUTICALS LLC (US) | 2022-12-08 | — | — | US | disclosed |
| US-20180271979-A1 | TRANS CAROTENOIDS, THEIR SYNTHESIS, FORMULATION AND USES | DIFFUSION PHARMACEUTICALS LLC (US) | 2018-09-27 | — | — | US | disclosed |
| US-9950067-B2 | Trans carotenoids, their synthesis, formulation and uses | Diffusion Pharmaceuticals, LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160199490-A1 | TRANS CAROTENOIDS, THEIR SYNTHESIS, FORMULATION AND USES | Diffusion Pharmaceuticals, LLC | 2016-07-14 | — | — | US | disclosed |
| WO-2015116485-A1 | PYRAZOLE COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-06 | — | — | WO | disclosed |
| US-20120095099-A1 | Trans carotenoids, their synthesis, formulation and uses | DIFFUSION PHARMACEUTICALS LLC (US) | 2012-04-19 | — | — | US | disclosed |
| US-8030350-B2 | Trans carotenoids, their synthesis, formulation and uses | DIFFUSION PHARMACEUTICALS LLC (US) | 2011-10-04 | — | — | US | disclosed |
| US-20060194973-A1 | Trans carotenoids, their synthesis, formulation and uses | DIFFUSION PHARMACEUTICALS LLC (US) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160199490-A1 | TRANS CAROTENOIDS, THEIR SYNTHESIS, FORMULATION AND USES | TTPA, RBP4, TXNRD2 | KCNH2 4714/4885HRH3 4397/4885MAPT 1885/4885 |
| US-20220387589-A1 | TRANS CAROTENOIDS, THEIR SYNTHESIS, FORMULATION AND USES | TTPA, RBP4, TXNRD2 | KCNH2 4714/4885HRH3 4397/4885MAPT 1885/4885 |
| US-20060194973-A1 | Trans carotenoids, their synthesis, formulation and uses | TTPA, RBP4, TXNRD2 | KCNH2 4714/4885HRH3 4397/4885MAPT 1885/4885 |
| US-20180271979-A1 | TRANS CAROTENOIDS, THEIR SYNTHESIS, FORMULATION AND USES | TTPA, RBP4, TXNRD2 | KCNH2 4714/4885HRH3 4397/4885MAPT 1885/4885 |
| US-20120095099-A1 | Trans carotenoids, their synthesis, formulation and uses | TTPA, RBP4, TXNRD2 | KCNH2 4714/4885HRH3 4397/4885MAPT 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.